Talphera (NASDAQ:TLPH) Releases Earnings Results, Hits Expectations

Talphera (NASDAQ:TLPH) released its quarterly earnings data on Wednesday. The company reported ($0.06) earnings per share for the quarter, meeting the consensus estimate of ($0.06), FiscalAI reports.

Here are the key takeaways from Talphera’s conference call:

• NEPHRO-CRRT enrollment reached 75%, with all clinical sites activated and completion still expected later this year. Top-line data is anticipated approximately four to five weeks after enrollment concludes.
• The draft 2026 KDIGO guideline references nafamostat as an acceptable regional anticoagulant alternative to citrate, potentially supporting future adoption if approved. Management said the final guideline could be published within roughly three to six months, although U.S. institutional uptake may vary.
• Updated market research increased the estimated U.S. CRRT opportunity to approximately 200,000 annual procedures in 2027, up 21% from the prior estimate of 165,000. Management expects the market to be concentrated, with about 70 institutions representing more than half of procedures.
• Investigators have reported straightforward and predictable monitoring and titration, while an independent safety review identified no new patient risks. Management said most patients remained below half the maximum permitted dose and generally required few titration adjustments, though final results remain blinded.
• Talphera had $17.1 million in cash at June 30, 2026, and expects two conditional financing tranches totaling approximately $16 million to fund operations through a potential 2027 PMA approval. The additional capital depends on the financing conditions being met, and quarterly cash operating expenses rose to $3.7 million excluding stock-based compensation.

Talphera Trading Down 4.8%

TLPH stock traded down $0.07 during mid-day trading on Wednesday, hitting $1.40. 497,706 shares of the company were exchanged, compared to its average volume of 246,845. The business has a 50 day simple moving average of $1.18 and a 200-day simple moving average of $0.95. The stock has a market capitalization of $72.66 million, a PE ratio of -4.52 and a beta of 0.69. Talphera has a 1-year low of $0.40 and a 1-year high of $1.57.

Hedge Funds Weigh In On Talphera

Large investors have recently made changes to their positions in the company. Group One Trading LLC boosted its stake in Talphera by 3,224.0% in the 3rd quarter. Group One Trading LLC now owns 30,415 shares of the company’s stock valued at $27,000 after purchasing an additional 29,500 shares during the period. Dauntless Investment Group LLC bought a new stake in shares of Talphera in the third quarter valued at about $89,000. Virtu Financial LLC acquired a new position in shares of Talphera in the third quarter valued at about $29,000. Nantahala Capital Management LLC increased its position in Talphera by 75.3% during the third quarter. Nantahala Capital Management LLC now owns 3,492,519 shares of the company’s stock worth $3,120,000 after acquiring an additional 1,500,000 shares during the period. Finally, Geode Capital Management LLC increased its position in Talphera by 107.0% during the fourth quarter. Geode Capital Management LLC now owns 342,987 shares of the company’s stock worth $391,000 after acquiring an additional 177,294 shares during the period. Institutional investors own 37.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on TLPH. HC Wainwright assumed coverage on Talphera in a research report on Friday, June 5th. They set a “buy” rating and a $3.00 price target for the company. Zacks Research upgraded shares of Talphera to a “hold” rating in a research note on Monday, June 8th. Westpark Capital began coverage on shares of Talphera in a report on Thursday, April 30th. They issued a “buy” rating and a $3.00 target price on the stock. Wall Street Zen upgraded shares of Talphera to a “hold” rating in a research note on Saturday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Talphera in a research report on Friday, July 17th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $3.00.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.